ARCA biopharma
8001 Arista Place
Suite 200
Broomfield
Colorado
80021
United States
Tel: 720-940-2100
Fax: 720-208-9261
Website: http://www.arcabiopharma.com/
169 articles with ARCA biopharma
-
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
2/24/2023
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, reported 2022 financial results and provided a corporate update.
-
James Flynn Joins ARCA biopharma Board of Directors
12/19/2022
ARCA biopharma, Inc. announced that James Flynn has joined its Board of Directors.
-
ARCA biopharma Announces Third Quarter 2022 Financial Results
10/28/2022
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update.
-
ARCA biopharma Announces Second Quarter 2022 Financial Results
8/2/2022
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update.
-
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
6/21/2022
ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors.
-
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
5/5/2022
ARCA biopharma, Inc. announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor.
-
ARCA biopharma Announces First Quarter 2022 Financial Results
5/2/2022
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.
-
ARCA biopharma Establishes Special Committee of the Board of Directors
4/18/2022
ARCA biopharma, Inc. today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Although the data suggests the vaccines are extremely effective and generally safe, analysis is still coming in about adverse events as well as effectiveness in specific patient populations.
-
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial
3/31/2022
ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN-COVID-19, a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly potent and specific inhibitor of tissue factor, as a potential treatment for patients hospitalized with COVID-19.
-
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update
3/14/2022
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, reported 2021 financial results and provided a corporate update.
-
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
1/4/2022
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the paper entitled “Dose Limiting, Adverse Event Associated Bradycardia with β-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial” (William Abraham, et al) has been published in Heart Rhythm O2, a publication of the Hearth Rhythm Society.
-
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
-
ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19
12/2/2021
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.
-
ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
11/2/2021
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, reported third quarter 2021 financial results and provided a corporate update.
-
Clinical Catch-Up: October 25-29
11/1/2021
Yet another busy week for clinical trial news. Here’s a look. -
ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data
10/28/2021
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today provided an update on the ASPEN-COVID-19 Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with severe COVID-19.
-
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
9/16/2021
ARCA biopharma, Inc. today announced that the first international patient has been enrolled in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for patients hospitalized with COVID-19.